Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine
Open Access
- 8 March 2024
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-10
Abstract
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB) in a phase 2b, placebo-controlled, randomized, controlled human infection model study (NCT03527173) enrolling healthy United States adults aged 18–50 years. We report analyses evaluating immune responses to vaccination, with the aim to identify correlates of risk for shigellosis among assessed immunomarkers. We found that 1790GAHB elicited S. sonnei lipopolysaccharide specific α4β7+ immunoglobulin (Ig) G and IgA secreting B cells which are likely homing to the gut, indicating the ability to induce a mucosal in addition to a systemic response, despite parenteral delivery. We were unable to establish or confirm threshold levels that predict vaccine efficacy facilitating the evaluation of vaccine candidates. However, serum anti-lipopolysaccharide IgG and bactericidal activity were identified as potential correlates of risk for shigellosis.Keywords
All Related Versions
Funding Information
- Bill and Melinda Gates Foundation
This publication has 53 references indexed in Scilit:
- Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials dataClinical Microbiology and Infection, 2022
- GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on NeutropeniaInfectious Diseases and Therapy, 2022
- Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adultseClinicalMedicine, 2021
- Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccineEBioMedicine, 2021
- Shigella sonnei: virulence and antibiotic resistanceArchives of Microbiology, 2020
- Antibiotic-Resistant Enteric InfectionsInfectious Disease Clinics of North America, 2019
- Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeEBioMedicine, 2017
- A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivityVaccine, 1995
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Comparative analysis of two ratesStatistics in Medicine, 1985